Hematologic Oncology

John M. Burke, MD discussed ongoing investigations into the treatment of lymphoma that were presented at ASCO 2024.

Axi-cel administration was safe and clinically active in relapsed/refractory primary and secondary central nervous system lymphoma.

Enrollment of patients in a phase 2 study evaluating SLS009 in relapsed/refractory AML has been completed and the agent demonstrated initial efficacy.

SL-172154 has been granted orphan drug designation from the FDA in acute myeloid leukemia.

Timothy Hughes, MD, MBBS, FRACP, FRCPA discussed findings from the ASC4FIRST trial comparing asciminib vs investigator-selected TKIs in CP-CML.

Eunice S. Wang, MD, discusses current unmet needs and efforts to move menin inhibitors into earlier lines of therapy in relapsed/refractory AML.

The European Commission granted orphan drug designation to UCART22 for acute lymphoblastic leukemia.

A clinically meaningful but not statistically significant improvement in OS was observed with uproleselan plus chemotherapy vs chemotherapy alone in primary refractory AML.

Treatment with a decreased dosing schedule of oral azacitidine was consistent with what has been previously known about the agent in intermediate-risk myelodysplastic syndrome.

Tucidinostat plus R-CHOP improved efficacy and was safe in previously untreated DLBCL expressing MYC and BCL2.

Four-year progression-free survival outcomes revealed the BrECADD regimen was superior to the eBEACOPP regimen, and BrECADD had a promising benefit-risk profile.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Ponatinib generated long-term efficacy and displayed manageable safety in chronic-phase chronic myeloid leukemia harboring a T315I mutation.

Treatment with asciminib led to a superior 48-week major molecular response rate vs investigator-selected TKIs in patients with Ph-positive chronic phase chronic myeloid leukemia.

Dr. Constantine Tam provides an overview of the current and emerging treatment landscape for chronic lymphocytic leukemia (CLL), with a focus on Bruton's tyrosine kinase (BTK) inhibitors like ibrutinib and the next generation of BTK inhibitors under development.

Katie S. Gatwood, PharmD, BCOP, explains next steps with novel agents in the hematologic oncology field that have the potential to change practice.

Carrie L. Kitko, MD, discusses the use of obecabtagene autoleucel for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Lori A. Leslie, MD, discusses the utility of treatment with axi-cel through the lens of the ZUMA-7 trial in large B-cell lymphoma.

Craig Eckfeldt, MD, PhD, discusses key updates in the MDS treatment paradigm and the implications of MRD testing, as well as next steps in the field of AML.

Carrie L. Kitko, MD, discusses the current standing of cellular therapies in adult and pediatric ALL and looks toward future developments.

Sattva S. Neelapu, MD, discusses the optimal processes of CAR T-cell therapy administration and the remaining unmet needs in the space.

WU-CART-007 has received RMAT and PRIME designations in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Sattva S. Neelapu, MD, discusses the current standing of CAR T-cell therapies in the treatment paradigm in lymphoma.

The FDA has granted accelerated approval to lisocabtagene maraleucel for the treatment of select adult patients with relapsed or refractory follicular lymphoma.

Lori A. Leslie, MD, discusses the evolution in managing toxicities associated with CAR T-cell therapy in patients with LBCL.